Nutrition and metabolism: Non-alcoholic fatty liver disease - Pathogenesis, cardiovascular risk and therapy

Current Opinion in Lipidology

Volumn 19, Issue 1, 2008, Pages 92-94

  Watts, Gerald F ^a   Gan, Seng Khee ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TETRAHYDROLIPSTATIN;

APOPTOSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DYSLIPOPROTEINEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER CELL; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NUTRITION; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FATTY LIVER; HUMANS; METABOLISM; NUTRITION PHYSIOLOGY; RISK FACTORS;

EID: 38149078234     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f41b4f     Document Type: Editorial

References (24)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231.
2. Targher G, Arcaro G. Nonalcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007; 191:235-240.
3. Vega GL, Chandalia M, Szczepaniak LS, et al. Metabolic correlates of nonalcoholic fatty liver in women and men. Hepatology 2007; 46:716-722.
4. Calvert VS, Collantes R, Elariny H, et al. A systems biology approach to the pathogenesis of obesity-related nonalcoholic fatty liver disease using reverse phase protein microarrays for multiplexed cell signaling analysis. Hepatology 2007; 46:166-172.
5. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114:147-152.
6. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006; 4:185-198.
7. Ozcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306:457-461.
8. Toledo FGS, Sniderman AD, Kelley DE. Influence of hepatic steatosis (fatty liver) on severity and composition of dyslipidaemia in type 2 diabetes. Diabetes Care 2006; 29:1845-1850.
9. Adiels M, Taskinen M-R, Packard C, et al. Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006; 49:755-765.
10. Adiels M, Westerbacka J, Soro-Paavonen A, et al. Acute suppression of VLDL1 secretion rate by insulin is associated with hepatic fat content and insulin resistance. Diabetologia 2007; 50:2356-2365.
11. Matikainen N, Mänttä ri S, Westerbacka J, et al. Postprandial lipaemia associates with liver fat content. J Clin Endocrin Metab 2007; 92:3052-3059.
12. Kotronen A, Vehkavaara S, Seppala-Lindroos A, et al. Effect of liver fat on insulin clearance. Am J Physiol Endocrinol Metab 2007 [Epub ahead of print].
13. Ng TW, Watts GF, Farvid MS, et al. Adipocytokines and VLDL metabolism: independent regulatory effects of adiponectin, insulin resistance, and fat compartments on VLDL apolipoprotein B-100 kinetics? Diabetes 2005; 54:795-802.
14. Kotronen A, Westerbacka J, Bergholm R, et al. Liver fat in the metabolic syndrome. J Clin Endocrin Metab 2007; 92:3490-3497.
15. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54:3541-3546.
16. Targher G, Bertolini L, Padovani R, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30:1212-1218.
17. Targher G, Bertolini L, Padovani R, et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006; 29:1325-1330.
18. Kotronen A, Juurinen L, Hakkarainen A et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum ALT compared to equally obese nondiabetic subjects. Diabetes Care 2007 [Epub ahead of print].
19. Westerbacka J, Lammi K, Hakkinen AM, et al. Dietary fat content modifies liver fat in overweight nondiabetic subjects. J Clin Endocrinol Metab 2005; 90:2804-2809.
20. Ryan MC, Abbasi F, Lamendola C, et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin resistant adults. Diabetes Care 2007; 30:1075-1080.
21. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New Engl J Med 2006; 355:2297-2307.
22. Lutchman G, Modi A, Kleiner DE, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology 2007; 46:424-429.
23. Tiikkainen M, Hakkinen AM, Korsheninnikova E, et al. Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 2004; 53:2169-2176.
24. Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on nonalcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006; 22:873-883.